EP Patent

EP4294525A1 — Dispersible formulations of n-((r)-2,3-dihydroxypropoxy)-3,4- difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof

Assigned to SpringWorks Therapeutics Inc · Expires 2023-12-27 · 2y expired

What this patent protects

The present disclosure relates to dispersible pharmaceutical compositions comprising N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide, and, optionally, a pharmaceutically acceptable carrier.

USPTO Abstract

The present disclosure relates to dispersible pharmaceutical compositions comprising N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide, and, optionally, a pharmaceutically acceptable carrier.

Drugs covered by this patent

Patent Metadata

Patent number
EP4294525A1
Jurisdiction
EP
Classification
Expires
2023-12-27
Drug substance claim
No
Drug product claim
No
Assignee
SpringWorks Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.